China relents to having FDA in country; Shire has rare stumble with eye drug;

@FiercePharma: Whooping cough is making a comeback--and the FDA thinks it might know why. Story from FierceVaccines | Follow @FiercePharma

@EricPFierce: Mylan intends to launch 800 injectable products in next 5 years, 150 in US, now that it own Agila. Yesterday's story | Follow @EricPFierce

@CarlyHFierce: NICE smiles on Sanofi's Aubagio the day after snubbing Lemtrada. Story | Follow @CarlyHFierce

> China has finally agreed to allow the FDA to station 10 FDA inspectors in that country. Report

> An FDA panel next week will discuss tablets from Merck ($MRK) and Stallergenes for treating grass pollen allergies. Story (sub. req.)

> Shire ($SHPG), which has been doing really well, has stumbled with its recently acquired eye drug. Story

> Lupin has launched in the U.S. its generic version of AbbVie's ($ABBV) Trilipix delayed-release capsules for reducing cholesterol. Item

> Teva Pharmaceutical Industries ($TEVA) has launched in the U.S. a generic version of Medicis Pharmaceutical's Aldara for treating warts and skin lesions. Report

> A Cleveland, OH, cardiologist, speaking at a seminar by the American Enterprise Institute, has questioned the effectiveness of some of the drugs made by Ranbaxy Laboratories. Story

Medical Device News

@FierceMedDev: Biocartis and VIB join forces to develop unique diagnostic cancer test. Release | Follow @FierceMedDev

@MarkHFierce: An Xconomy contributor offers another point-of-vew on the 23andMe issue - a clash of cultures and business models. More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: 'Worm-shaped' nanoparticles best at infiltrating breast cancer. Story from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: China finally allows the FDA to add inspectors to bolster oversight. More | Follow @GalenMoore

> Jarvik Heart's Japan regulatory win gives Thoratec a new heart pump challenge. Story

> Thermo's 'ever-increasing appetite for debt' raises analysts' eyebrows. Article

> 23andMe capitulates, yanking all health-related gene tests pending FDA review. Report

> Medtronic's spinal division generates a shot of good news. More

> Sorin collects EU approval for its Intensia family of cardiac devices. Item

Biotech News

@FierceBiotech: Chutes & Ladders this week: GoBalto gets new CEO as founder Chung steps down & more. Feature | Follow @FierceBiotech

@JohnCFierce: Mixed outcome for lifitegrast PhIII, 1 of Fleming Ornskov's 1st deals for Shire-$160M SARcode buyout - hit 1 missed. Release | Follow @JohnCFierce

@DamianFierce: So Geron is soaring on these imetelstat results "embargoed" for Monday. More | Follow @DamianFierce

@EmilyMFierce: With drug-resistant malaria strains on the rise, a new report says basic research for malaria needs a boost. Story | Follow @EmilyMFierce

> Biotech vet joins R&D troika to take compounds from campus to clinic. Story

> Shire's new CEO sees one of his first-round biotech deals sour in PhIII. Article

> Novartis hits PhIII paydirt with promising myeloma drug. Report

> Geron soars as marrow cancer drug shines in preliminary results. Story

And Finally... A survey conducted for Medical Marketing & Media found that some doctors will hold off before moving patients to sofosbuvir, the new hepatitis C treatment from Gilead Sciences ($GILD) expected to be approved any day now by the FDA. Story

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.